linjc16/ctgov huggingface dataset:
Dresden Glaucoma and Treatment Study (DGTS)

Study Overview
=================
Brief Summary
-----------------
To assure the quality of follow-up and treatment, data of glaucoma patients are stored and evaluated after anonymisation.

Detailed Description
-----------------
The aim of the study is to evaluate the quality of follow-up and treatment by means of consecutive data collection and anonymised analysis of all glaucoma patients of a tertiary university hospital glaucoma service. Parameters being analyzed are: Age, sex, refraction, family history, known duration of glaucoma, highest intraocular pressure before treatment, systemic and topical medication, previous ocular surgery. 24h Goldmann-applanation tonometry, biomicroscopy, gonioscopy, Heidelberg Retinal Tomograph (HRT), glaucoma diagnosis with Scanning-Laser-Polarimetry (GDx), optical coherence tomography (OCT), Pentacam, Ocular Response Analyzer (ORA), Corvis ST (Corneal Visualization with the Scheimpflug Technology), perimetry

Official Title
-----------------
Dresden Glaucoma and Treatment Study: Analysis to Assure the Quality of Follow-up and Therapy of Glaucoma Patients in a Tertiary University Hospital Glaucoma Service.

Conditions
-----------------
Glaucoma, Glaucoma, Open-Angle, Glaucoma, Angle-Closure, Glaucoma, Low Tension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: manifest glaucoma, ocular Hypertension, glaucoma suspect Exclusion Criteria: under 18 years of age, corneal diseases
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Follow-up intervals | To find the best follow-up intervals for glaucoma patients. | 20 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of treatment quality | What is the best treatment option for the individual patient? | 20 years | 
| Assessment of intraocular pressure-lowering efficacy and number of participants with treatment-related adverse events as assessed by CTCAE v4.0 of glaucoma laser therapy | Diurnal intraocular pressure, best corrected visual acuity, visual fields | 20 years | 
| Assessment of intraocular pressure-lowering efficacy and number of participants with treatment-related adverse events as assessed by CTCAE v4.0 of glaucoma laser therapy of glaucoma surgery | Diurnal intraocular pressure, best corrected visual acuity, visual fields | 20 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Follow-up intervals, Treatment Efficiency, Laser Therapy, Glaucoma Surgery, Minimal Invasive Glaucoma Surgery (MIGS)
Short-course Antibiotic Treatment in AECOPD: a Meta-analysis of Double-blind Studies

Study Overview
=================
Brief Summary
-----------------
Chronic obstructive pulmonary disease (COPD) is a common disease worldwide and a leading cause of death and disability globally. Given that bacteria are implicated in a substantial proportion of acute exacerbation of COPD (AECOPD), antibiotics are frequently used. However, this current practice may lead to antibiotic overuse further increasing drug resistance and side effects. Although the small literature on interventions to prove the effective of short course of antibiotic, a metaanalysis of published randomised double-blind studies comparing the same antibiotics compared to a previous study is performed to determine whether a short course of antibiotic treatment is as effective as a very short course in patients with an exacerbation of COPD (EACOPD). The authors systematically searched electronic databases on the literature of controlled trials on Medline and Embase with no language, location, or time restrictions. The authors retrieved observational and controlled trials comparing different durations of the same oral antibiotic therapy in the treatment of acute exacerbations of COPD. The authors included 30 randomized, placebo-controlled trials for COPD patients. There was no statistically significant difference between shorter and longer antibiotic courses in early clinical success. In conclusion, Short-course antibiotic treatment is as effective as very short-course treatment in patients with mild to moderate exacerbations of chronic bronchitis and COPD.

Official Title
-----------------
Short-course Versus Very Short-course Antibiotic Treatment in Acute Exacerbations of COPD: a Meta-analysis of Double-blind Studies

Conditions
-----------------
COPD Exacerbation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Studies considered eligible for inclusion were randomised trials of antibiotic intervention involving adult patients >18 years of age with a diagnosis of AECOPD. Exclusion Criteria: Studies not published in the English language or with more than two or different antibiotics were excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Short-course<br>Group with short treatment of antibiotic of <= 5 days | |
| Very short-course<br>Group with short treatment of antibiotic of <= 3 days | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical success | clinical cure at early follow-up | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AECOPD, antibiotic treatment, meta analysis, short course, Forest plot
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3 study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.

Detailed Description
-----------------
To contribute greater treatment compliance and patient convenience, the rebamipide SR formulation has been developed.

Official Title
-----------------
A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Phase 3 Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis

Conditions
-----------------
Acute Gastritis, Chronic Gastritis

Intervention / Treatment
-----------------
* Drug: MCT-SR
* Drug: Mucosta Tab.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult males and females aged ≥19 and <75 years Patients diagnosed with acute or chronic gastritis by gastroscopy with at least 1 erosion confirmed by gastroscopy within 7 days prior to the first dose of the Investigational Product(IP) Exclusion Criteria: Patients ineligible for gastroscopy Patients who took other drugs for treating gastritis within 2 weeks prior to the first dose of the IP. Patients who have to continue taking drugs that may induce gastritis Other clinically significant medical or psychiatric findings that the investigator considers inappropriate for the study

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MCT-SR<br>Drug: MCT-SR 2 times/day for 2 weeks | Drug: MCT-SR<br>* Rebamipide 150mg<br>Drug: Mucosta Tab.<br>* Rebamipide 100mg<br>* Other names: Mucosta;|
| Active Comparator: Mucosta Tab.<br>Drug: Mucosta Tab. 3 times/day for 2 weeks | Drug: MCT-SR<br>* Rebamipide 150mg<br>Drug: Mucosta Tab.<br>* Rebamipide 100mg<br>* Other names: Mucosta;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endoscopic Improvement Rate | The percentage of subjects with improvement refer to those with more than 50% improvement in erosion score on gastroscopy after treatment compared to the score before treatment. | 2 weeks |
Sarcopenic Obesity in Neurodisabilities

Study Overview
=================
Brief Summary
-----------------
To describe the frequency and thresholds for sarcopenic obesity in neurodisabled persons and the fat and lean mass distribution based on various neurodisabilities

Official Title
-----------------
Sarcopenic Obesity in Neurodisabled People

Conditions
-----------------
Traumatic Brain Injury, Sarcopenic Obesity, Spinal Cord Injuries, Stroke, Multiple Sclerosis

Intervention / Treatment
-----------------
* Diagnostic Test: whole body DXA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons with stroke / cerebrovascular disease traumatic brain injury multiple sclerosis spinal cord injuries (including spinal cord lesions i.e. myelopathies etc.) Exclusion Criteria: Persons with heterotopic ossifications, chronic administration of drugs, which promote fat increase chronic administration of drugs, which promote bone or muscle loss co-existing other diseases such as: endocrinopathies, muscular dystrophies, non-alcoholic fatty liver disease.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurodisabled persons<br>Persons with various neurodisabilities | Diagnostic Test: whole body DXA<br>* Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.<br>|
| Control group<br>Able bodied persons | Diagnostic Test: whole body DXA<br>* Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fat and lean mass in neurodisabled |  | an average of 1 year | 
| Frequency of sarcopenic obesity |  | an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body mass index correlation with fat mass and visceral fat |  | an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sci, Sarcopenia, sarcopenic obesity, stroke, TBI, MS
Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy

Study Overview
=================
Brief Summary
-----------------
About 30% of breast cancers have higher than normal levels of a cellular marker called HER2. The amount of HER2 is often measured in breast tissue. A higher level of this marker usually indicates a more aggressive type of breast cancer. Cytokeratin is a second cellular marker found in breast cancer cells. Detection of Circulating cytokeratin in the blood could indicate the presence of cancer. The Pathology Department of the Tom Baker Cancer Center is doing this study to see if measuring the levels of circulating HER2 and cytokeratin, through blood testing has clinical significance for patients with breast cancer.

Detailed Description
-----------------
Single Variate analysis will be performed to correlate variables such as tumour size, grade, stage, ER status, PR status and biopsy HER2 status with soluble HER2 levels. Soluble HER2 levels will be analyzed as both a continuous and categorized variable. The analysis will attempt to discern the relationship between soluble HER2 levels, HER2 positive circulating epithelial cell level and treatment response. This will provide evidence of the effect various treatments have on HER2 levels. HER2 levels both in patients treated with Herceptin and those on other treatment protocols, will be related to clinical disease measures such as time to progression, time to failure, duration of response and duration of survival. An initial model of the relationship between these factors and soluble HER2 as a marker will be established from the data.

Official Title
-----------------
Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: Blood Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Albertan women with breast cancer who will undergo Herceptin therapy as part of their treatment at some point during a one-year period. Exclusion Criteria: Greater than 80 years of age Previous cancer diagnosis - (other than skin cancer)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Cancer, Herceptin Therapy
Removing Background Talker Noise for Cochlear Implant Users

Study Overview
=================
Brief Summary
-----------------
When hearing-impaired listeners are properly aided with a hearing aid (HA) or cochlear implant (CI), they are often able to comfortably maintain a conversation in quiet environments. However, in group environments, such as a large family dinner, restaurant, or other environment where multiple people are talking simultaneously, hearing-impaired listeners have great difficulty participating in conversations and frequently withdraw or avoid the situation. As such, it would be highly beneficial to implement an algorithm into HAs or CIs to remove background talkers (babble) from the signal to reduce listening effort for the hearing-impaired listener and allow them to converse as if they were in a quiet environment. Although HAs and CIs frequently incorporate noise reduction algorithms, these algorithms are not effective when the background is babble. The problem of removing babble involves segregating speech from speech. Hence, the spectral properties of the signal and noise are extremely similar. Despite these challenges, we developed an algorithm to remove background babble. In the following study will test the ability of cochlear implant users to understand speech with background babble noise using our noise reduction algorithm or no noise reduction algorithm. We hypothesize that CI users will be able to understand significantly more speech in babble noise when using our algorithm.

Official Title
-----------------
Removing Background Talker Noise for Cochlear Implant Users

Conditions
-----------------
Hearing Loss

Intervention / Treatment
-----------------
* Other: Noise Reduction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with CIs 12 years of age and older with no diagnosis of other communicative or cognitive disorders. Subjects must have native or native-like English proficiency. Exclusion Criteria: No diagnosed cognitive or communicative disorders (other than hearing loss), presence of acute/chronic otitis media, useable acoustic hearing, and non-English speaking.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experiment<br>Subjects will be tested for their ability to understand speech with and without noise reduction | Other: Noise Reduction<br>* In within subject design, listeners will have background noise removed by a noise reduction algorithm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Speech Recognition | The % of words correctly understood in various noisy situations will be measured | 1 day |
Postoperative Pain and Venipuncture Pain

Study Overview
=================
Brief Summary
-----------------
Association between venipuncture pain and postoperative pain

Detailed Description
-----------------
Association will be find between venipuncture pain and postoperative pain in sleeve gastrectomy patients. Also we can study with pain catastrophising scale.

Official Title
-----------------
Association Between Postoperative Pain and Venipuncture Pain in Sleeve Gastrectomy Patients

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Other: venipuncture pain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sleeve gastrectomy Exclusion Criteria: psychotic illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: venipuncture pain<br>pain during venipuncture | Other: venipuncture pain<br>* postoperative sleeve gastrectomy patients pain<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| numeric rating scale | pain intensity 0 to 10 during venipuncture | 3 months |
The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the daily use of a certain amount and type of milk component for 2 months provides a significant stimulation to the immune system and specifically increases the chances of being protected against pneumonia after the vaccination.

Official Title
-----------------
The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens: A Randomized Placebo-controlled Clinical Trial

Conditions
-----------------
The Effect of Milk Components on the Response to Pneumococcal Vaccines in the Elderly

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age and a willingness to participate Exclusion Criteria: • Smoking history within 10 years Underlying neoplasia or immunological disease Use of oral cortisone or other immunosuppressive agents Current consumption of milk and milk products greater than 1 unit of milk, 1 yogurt, or 1 serving of fresh cheese a day. Food faddists or those taking a non-traditional diet Current consumption of dietary supplements People with a known history of milk allergy People with chronic renal failure People with chronic inflammatory diseases taking daily doses of NSAIDs for longer than 4 weeks at the time of enrollment. Previous administration of the pneumomax vaccine Reduced physical activity (i.e. NYHA classes III-IV)

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to develop an emergency electroencephalogram (EEG) device, StatNet, that can be placed quickly by minimally-trained personnel and interpreted remotely for rapid identification of seizures.

Official Title
-----------------
Evaluation of StatNet Device for EEG Recordings

Conditions
-----------------
Epilepsy, Seizures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults > age 18 Epileptiform discharges present on routine EEG Exclusion Criteria: Open head wounds Medically Unstable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
New onset seizures
The Analysis of BMI, Asthma Prevalence, and Lung Functions of Schoolchildren in Southern Taiwan

Study Overview
=================
Brief Summary
-----------------
The prevalence of obesity and asthma has increased in recent decades. We investigated the relationship between body mass index (BMI) and lung function, and also tried to determine if asthma prevalence differs between obese and non-obese children. We propose this cross-sectional, retrospective analysis to figure out whether the BMI is associated with elevated prevalence of asthma, and how their lung function changes in different BMI groups.

Conditions
-----------------
Asthma, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: students representing all grades in a total of 123 junior high schools in southern Taiwan (Kaohsiung and Pintong) between 1995-1996 Exclusion Criteria: failure to obtain ISAAC questionnaire failure to preform lung functions study

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, pulmonary function tests, obesity